BioSpace News Archive

According to the current analysis of Emergen Research, the global Active Psoriatic Arthritis Market was valued at USD 7.15 billion in 2019 and is expected to reach USD 13.64 billion by 2027, at a CAGR of 9.2%.Psoriatic arthritis is a chronic inflammatory disease that occurs in individuals suffering from psoriasis

The global artificial organs market is expected to reach USD 32.62 Billion by 2027, according to a new report by Emergen Research. The market is anticipated to witness a CAGR of 11.8% from 2020 to 2027.

The global Chronic Rhinosinusitis Market was valued at USD 2132.5 million in 2019 and is expected to reach USD 3508.0 million by 2027, at a CAGR of 7.4%, According to the current analysis of Emergen Research.

The global gene editing Market is projected to reach USD 15.79 billion by 2027, according to a recent report by Emergen Research. The market is expected to grow at a CAGR of 17.2% over the forecast period (2020-2027).

The genome engineering market has been anticipated to experience noteworthy growth opportunities in the forthcoming years. The increasing market growth has been primarily driven by different factors such as the growing number of genomics projects.

SHINE Technologies, LLC, a next-generation fusion technology company, announced Tom D’Orazio has joined as the CEO of Phoenix LLC.

EvoNexus, California’s leading non-profit tech incubator, selected CRISPR QC to become a portfolio company.

Chicago Pacific Founders is pleased to announce that it, along with Magruder Eye Institute and Robson Eye Institute, has formed Ascend Vision Partners.

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $13.8 million, prior to deducting underwriting discounts and commissions and offering expenses.

IN8bio, Inc. today announced the closing of its previously announced underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90 per share.